The STOP-PKD study is a new multicentric study involving several European countries and universities, investigating a potential new treatment option for people living with autosomal dominant polycystic kidney disease (ADPKD). The study focuses on dapagliflozin, a medicine from the SGLT2 inhibitor class that is already approved and widely used for several other kidney diseases. Until now, however, people with ADPKD have been excluded from clinical trials with this type of medication.

This important study, led by the University of Cologne, aims to address this gap by exploring whether dapagliflozin could also help slow disease progression or provide clinical benefits for people with ADPKD.

Learn More

To find out more about this study, download the info flyer below and visit the official STOP-PKD study website: stop-pkd.de/en

Download Study Info Flyer (PDF)

Need Support or Have Questions?

If you have any questions, we encourage you to contact your nearest trial centre, which can be easily identified through the interactive map available on the official STOP-PKD website.

You may also write to us at for further support — we will be happy to assist you and connect you with your local patient association.

Useful Links

• Official STOP-PKD Study Website
• University of Cologne: STOP-PKD Study News
• PubMed Central: STOP-PKD Research Article

PKD International is proud to collaborate on the ARTICYST study, an innovative research initiative focused on improving the prediction of clinically relevant outcomes in autosomal dominant polycystic kidney disease (ADPKD). The most common genetic kidney disease, ADPKD affects more than 7 million people worldwide.

One of the key challenges in ADPKD is predicting how quickly kidney function will decline, particularly at a young age. This information is crucial for patients and families when making important life decisions, including career planning, family planning, and access to treatment options.

The ARTICYST project aims to address this challenge by developing advanced predictive models through the integration of diverse data sources. By leveraging Open Science practices, the study is building a comprehensive infrastructure for data sharing and analysis, with the goal of improving both individual patient decision-making and broader therapeutic strategies.

This ambitious collaboration brings together leading clinical partners and researchers across Europe, integrating new types of data to generate deeper insights into disease progression and management, ultimately contributing to more personalised and effective care for people living with ADPKD.

At PKD International, we are particularly proud to contribute to this project by actively engaging patients, ensuring that their perspectives, priorities, and real-world experiences are embedded throughout the research process.

Find out more about the ARTICYST study on the official project website

Have Your Say: European Survey on AI and Open Science in ADPKD

Are you living with ADPKD? Your voice matters.

As part of the ARTICYST project, PKD International invites patients to take part in a European research survey exploring the role of Artificial Intelligence and Open Science in kidney care. Your input will directly help guide researchers, clinicians, and policymakers across Europe.

Take the ARTICYST Survey

By sharing your views, you help ensure that patients remain at the heart of future PKD research and innovation.